Correlation Between Arcus Biosciences and SAB Biotherapeutics

Can any of the company-specific risk be diversified away by investing in both Arcus Biosciences and SAB Biotherapeutics at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Arcus Biosciences and SAB Biotherapeutics into the same portfolio, which is an essential part of the fundamental portfolio management process.

By analyzing existing cross correlation between Arcus Biosciences and SAB Biotherapeutics, you can compare the effects of market volatilities on Arcus Biosciences and SAB Biotherapeutics and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Arcus Biosciences with a short position of SAB Biotherapeutics. Check out your portfolio center. Please also check ongoing floating volatility patterns of Arcus Biosciences and SAB Biotherapeutics.

Diversification Opportunities for Arcus Biosciences and SAB Biotherapeutics

-0.15

Correlation Coefficient

Arcus Biosciences  SAB Biotherapeutics

Good diversification

The 3 months correlation between Arcus and SAB is -0.15. Overlapping area represents the amount of risk that can be diversified away by holding Arcus Biosciences and SAB Biotherapeutics in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on SAB Biotherapeutics and Arcus Biosciences is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Arcus Biosciences are associated (or correlated) with SAB Biotherapeutics. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of SAB Biotherapeutics has no effect on the direction of Arcus Biosciences i.e., Arcus Biosciences and SAB Biotherapeutics go up and down completely randomly.

Pair Corralation between Arcus Biosciences and SAB Biotherapeutics

Given the investment horizon of 90 days Arcus Biosciences is expected to generate 48.67 times less return on investment than SAB Biotherapeutics. But when comparing it to its historical volatility, Arcus Biosciences is 7.77 times less risky than SAB Biotherapeutics. It trades about 0.02 of its potential returns per unit of risk. SAB Biotherapeutics is currently generating about 0.15 of returns per unit of risk over similar time horizon. If you would invest  4.36  in SAB Biotherapeutics on September 25, 2024 and sell it today you would earn a total of  4.64  from holding SAB Biotherapeutics or generate 106.42% return on investment over 90 days.

Time Period	3 Months [change]
Direction	Moves Against
Strength	Insignificant
Accuracy	88.89%
Values	Daily Returns

Arcus Biosciences  vs.  SAB Biotherapeutics

Arcus Biosciences

Risk-Adjusted Performance

1 of 100

Weak

Compared to the overall equity markets, risk-adjusted returns on investments in Arcus Biosciences are ranked lower than 1 (%) of all global equities and portfolios over the last 90 days. In spite of comparatively stable basic indicators, Arcus Biosciences is not utilizing all of its potentials. The latest stock price uproar, may contribute to short-horizon losses for the private investors.

SAB Biotherapeutics

Risk-Adjusted Performance

12 of 100

Good

Compared to the overall equity markets, risk-adjusted returns on investments in SAB Biotherapeutics are ranked lower than 12 (%) of all global equities and portfolios over the last 90 days. In spite of fairly unsteady basic indicators, SAB Biotherapeutics showed solid returns over the last few months and may actually be approaching a breakup point.

Pair Trading with Arcus Biosciences and SAB Biotherapeutics

The main advantage of trading using opposite Arcus Biosciences and SAB Biotherapeutics positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Arcus Biosciences position performs unexpectedly, SAB Biotherapeutics can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in SAB Biotherapeutics will offset losses from the drop in SAB Biotherapeutics' long position.

The idea behind Arcus Biosciences and SAB Biotherapeutics pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.

Check out your portfolio center.

Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Equity Search module to search for actively traded equities including funds and ETFs from over 30 global markets.